Back to discover
Drug

Histidine

In clinical development
Emerging researchLate-stage development
Also known as (S)-a-Amino-1H-imidazole-4-propanoic acid, (S)-alpha-Amino-1H-imidazole-4-propionic acid, (S)-alpha-amino-1H-Imidazole-4-propanoic acid, Aminosyn 10%, Sulfite-Free+42 more

(S)-a-Amino-1H-imidazole-4-propanoic acid, (S)-alpha-Amino-1H-imidazole-4-propionic acid, (S)-alpha-amino-1H-Imidazole-4-propanoic acid, Aminosyn 10%, Sulfite-Free, Aminosyn 3.5 % M, Sulfite Free, Aminosyn 8.5 % with Electrolytes, Sulfite-Free, Aminosyn 8.5%, Sulfite-Free, Aminosyn II 10 %, Aminosyn II 15%, Aminosyn II 8.5 % with Electrolytes, Sulfite-Free, Aminosyn II 8.5 %, Sulfite-Free, Aminosyn-HBC 7 %, Sulfite-Free, Aminosyn-PF 10 %, Sulfite-Free, Aminosyn-PF 7%, Clinisol 15, Freamine III 10, HIS, Hepatamine 8, Hepatasol, L-(-)-histidine, L-Histidin, L-Histidine, Nephramine, Plenamine, PremaSol, ProSol, ProcalAmine 3, Travasol 10, Travasol 10%, Trophamine, Trophamine 10 %, Trophamine 6 %, (S)-4-(2-Amino-2-carboxyethyl)imidazole, Histidina, Clinimix 4.25/10, Clinimix 4.25/25, Clinimix 4.25/5, Clinimix 5/15, Clinimix 5/20, Clinimix 5/25, Clinimix E 2.75/5, Clinimix E 4.25/10, Clinimix E 4.25/5, Clinimix E 5/15, Clinimix E 5/20, Clinimix E 5/25.

RxNorm5340ChEMBLCHEMBL17962UNII4QD397987E
3
Research papers
Latest activity
beta

Recent clinical, regulatory, research and industry developments relating to this drug.

Histidine Oral Supplementation as a Therapeutic Modality for Alzheimer's Disease

Clinical trial2026-04-01Withdrawn · ClinicalTrials.gov

Potential therapeutic implications of histidine catabolism by the gut microbiota in NAFLD patients with morbid obesity.

Research2023-12-01Cell reports. Medicine

Investigation of the metabolic and endocrinological differences between daily and weekly growth hormone replacement therapy, somapacitan, in patients with adult growth hormone deficiency: A real-world pilot study.

Research2023-09-01Medicine

Histaminergic Basis of Fatigue in Multiple Sclerosis

Clinical trial2022-10-30Withdrawn · ClinicalTrials.gov

Histaminergic Basis of Central Fatigue in Multiple Sclerosis - A Novel Approach

Clinical trial2020-08-07Completed · ClinicalTrials.gov

Emergence and clonal expansion of in vitro artemisinin-resistant Plasmodium falciparum kelch13 R561H mutant parasites in Rwanda.

Research2020-08-03Nature medicine

Profile

Identifiers & mechanism

Canonical identifiers, marketed brand names and mechanism, resolved across RxNorm, ChEMBL and ATC.

Canonical name
Histidine
Aliases & brands
(S)-a-Amino-1H-imidazole-4-propanoic acid(S)-alpha-Amino-1H-imidazole-4-propionic acid(S)-alpha-amino-1H-Imidazole-4-propanoic acidAminosyn 10%, Sulfite-FreeAminosyn 3.5 % M, Sulfite FreeAminosyn 8.5 % with Electrolytes, Sulfite-FreeAminosyn 8.5%, Sulfite-FreeAminosyn II 10 %Aminosyn II 15%Aminosyn II 8.5 % with Electrolytes, Sulfite-FreeAminosyn II 8.5 %, Sulfite-FreeAminosyn-HBC 7 %, Sulfite-FreeAminosyn-PF 10 %, Sulfite-FreeAminosyn-PF 7%Clinisol 15Freamine III 10HISHepatamine 8HepatasolL-(-)-histidineL-HistidinL-HistidineNephraminePlenaminePremaSolProSolProcalAmine 3Travasol 10Travasol 10%TrophamineTrophamine 10 %Trophamine 6 %(S)-4-(2-Amino-2-carboxyethyl)imidazoleHistidinaClinimix 4.25/10Clinimix 4.25/25Clinimix 4.25/5Clinimix 5/15Clinimix 5/20Clinimix 5/25Clinimix E 2.75/5Clinimix E 4.25/10Clinimix E 4.25/5Clinimix E 5/15Clinimix E 5/20Clinimix E 5/25
RxNorm CUI
5340
ChEMBL ID
CHEMBL17962
UNII
4QD397987E

Clinical trials

3 trials

The current development programme across all trial phases — status mix, phase distribution and the late-stage studies shaping the evidence base.

Development programme
CLINICALTRIALS.GOV · LIVE REGISTRY
3
registered trials across all phases
LATEST COMPLETION 2020
1
Late-stage (III+)
1
Completed
2
Discontinued
PHASE DISTRIBUTIONn = 3
Phase 11Phase 21Phase 41

Late-stage studies

Phase III+ trials still open or recently active — where late-stage evidence is being generated.

Histidine Oral Supplementation as a Therapeutic Modality for Alzheimer's Disease

WithdrawnPH IVWake Forest University Health Sciences2026

Recent completions

Trials that read out recently, adding to the completed evidence base.

Histaminergic Basis of Central Fatigue in Multiple Sclerosis - A Novel Approach

CompletedPH IUniversity of Miamin=182020

Research activity

3 papers

Key research shaping understanding of this drug, combining the latest publications with the most influential evidence.

Publications over time
20202023
Major research themes6
Endocrinology1Gastrointestinal Microbiome1Human Growth Hormone1Mutation, Missense1Non-alcoholic Fatty Liver Disease1Obesity, Morbid1
Journals, researchers & institutions
Top journals
  • Cell reports. Medicine1
  • Medicine1
  • Nature medicine1
Leading researchers
  • Abe I1
  • Abe M1
  • Ariey F1
  • Baudin J1
  • Beraza N1
  • Burcelin R1
  • Caimari A1
  • Campagne P1
Leading institutions
free-text, unnormalised
  • Centre Tecnològic de Catalunya1
  • Clinical Research Support Center1
  • Columbia University Irving Medical Center1
  • Dr. Josep Trueta Hospital1
  • Fukuoka University1
  • Fukuoka University Chikushi Hospital1

Related drugs

5 matches

Drugs sharing diseases, protein targets and literature with this one. Ranked by graph evidence (shared targets + diseases weighted above co-mentions).

Arginine

Studied across 2 of the same disease areas as Histidine in the shared literature.

2 shared diseases1 shared paper
Artemisinin

Studied across 2 of the same disease areas as Histidine in the shared literature.

2 shared diseases1 shared paper
Mannitol

Frequently co-studied with Histidine in the research literature.

1 shared paper
Phenol

Frequently co-studied with Histidine in the research literature.

1 shared paper
Somapacitan

Frequently co-studied with Histidine in the research literature.

1 shared paper
References & data sources
  • RxNorm (U.S. National Library of Medicine) — drug identity
  • ChEMBL (EMBL-EBI) & UniProt — pharmacology and targets
  • Europe PMC — research literature
  • ClinicalTrials.gov — clinical trials